Nomogram-based risk classification for predicting response to metastasis-directed stereotactic body radiotherapy in PSMA PET-staged oligorecurrent prostate cancer (PORTAL): an international, retrospective cohort study.

Saved in:
Bibliographic Details
Title: Nomogram-based risk classification for predicting response to metastasis-directed stereotactic body radiotherapy in PSMA PET-staged oligorecurrent prostate cancer (PORTAL): an international, retrospective cohort study.
Authors: Soeterik TFW; Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, Netherlands. Electronic address: t.f.w.soeterik@umcutrecht.nl., Miszczyk M; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Collegium Medicum - Faculty of Medicine, WSB University, Dąbrowa Górnicza, Poland., Peters M; Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, Netherlands; Department of Radiation Oncology, Radiotherapiegroep, Deventer/Arnhem, Netherlands., Bilski M; Radiotherapy Department, Affidea Nu-med Centre of Oncology Diagnostics and Therapy, Zamość, Poland; Clinics of Radiotherapy, Medical University of Lublin, Lublin, Poland., Francolini G; Department of Radiation Oncology, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy., Garlatti P; Department of Radiation Oncology, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy., Nicosia L; Department of Advanced Radiation Oncology, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Centre, Negrar di Valpolicella, Italy., Alongi F; Department of Advanced Radiation Oncology, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Centre, Negrar di Valpolicella, Italy; University of Brescia, Brescia, Italy., Mezeckis M; University of Latvia, Riga, Latvia; Sigulda Hospital Centre of Stereotactic Radiosurgery, Sigulda, Latvia., Kociolek J; Department of Radiation Oncology, Champalimaud Centre for the Unknown, Lisbon, Portugal., Greco C; Department of Radiation Oncology, Champalimaud Centre for the Unknown, Lisbon, Portugal., Techmański T; 3rd Department of Radiotherapy and Chemotherapy, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice, Poland., Huele EH; Division of Imaging and Oncology, University Medical Centre Utrecht, Utrecht, Netherlands., Teunissen FR; Department of Radiation Oncology, Radboud University Medical Centre, Nijmegen, Netherlands., Westhoff PG; Department of Radiation Oncology, Radboud University Medical Centre, Nijmegen, Netherlands., Vis W; Department of Radiation Oncology, Radiotherapiegroep, Deventer/Arnhem, Netherlands., Haverkort MAD; Department of Radiation Oncology, Radiotherapiegroep, Deventer/Arnhem, Netherlands., van der Voort van Zyp JRN; Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, Netherlands., Intven MPW; Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, Netherlands., van der Velden JM; Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, Netherlands., Shariat SF; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czechia; Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Department of Urology, Semmelweis University, Budapest, Hungary; Research Centre for Evidence Medicine, Urology Department, Tabriz University of Medical Sciences, Tabriz, Iran., Eppinga WSC; Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, Netherlands.
Source: The Lancet. Oncology [Lancet Oncol] 2026 Mar; Vol. 27 (3), pp. 383-392. Date of Electronic Publication: 2026 Feb 16.
Publication Type: Journal Article; Multicenter Study
Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1474-5488
DOI:10.1016/S1470-2045(25)00717-X